We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

115 hedge funds and large institutions have $57M invested in Sanofi Contingent Value Rights in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

4% more funds holding

Funds holding: 111 → 115 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15% less capital invested

Capital invested by funds: $67.2M → $57M (-$10.1M)

Holders
115
Holders Change
+4
Holders Change %
+3.6%
% of All Funds
2.87%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
20
Reduced
12
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonehill Capital Management
New York
+$2.55M
2
HCM
Highbridge Capital Management
New York
+$229K
3
SAM
Silverback Asset Management
North Carolina
+$184K
4
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO)
California
+$112K
5
AFM
Anson Funds Management
Texas
+$108K

Top Sellers

Rank Fund Capital Flow
1
PC
PointState Capital
New York
-$3.29M
2
RL
Ruffer LLP
United Kingdom
-$6K
3
FHA
Flagship Harbor Advisors
Massachusetts
-$5.31K
4
UBS Group
UBS Group
Switzerland
-$1.01K
5
BWM
Baystate Wealth Management
Massachusetts
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonehill Capital Management
New York
$15.1M +$2.55M +6,252,861 +19%
EM
2
Elliott Management
New York
$7.77M – – –
MCM
3
Mason Capital Management
New York
$5.57M – – –
TGHSA
4
TPG Group Holdings (SBS) Advisors
Texas
$5.41M – – –
BCM
5
Brigade Capital Management
New York
$4.66M – – –
WA
6
Whitebox Advisors
Minnesota
$2.73M – – –
FCM
7
Farallon Capital Management
California
$2.6M – – –
GCM
8
Gruss Capital Management
New York
$2.09M – – –
HCM
9
Highbridge Capital Management
New York
$1.45M +$229K +559,890 +17%
MFP
10
Michael F. Price
$1.36M – – –
NGA
11
New Generation Advisors
Massachusetts
$1.22M – – –
TAM
12
TFG Asset Management
Cayman Islands
$1.01M – – –
CL
13
CSS LLC
Illinois
$751K +$1.32K +3,247 +0.2%
AMH
14
Apollo Management Holdings
New York
$734K – – –
Citigroup
15
Citigroup
New York
$591K – – –
PC
16
Pomelo Capital
New York
$574K +$44.9K +110,000 +8%
AFM
17
Anson Funds Management
Texas
$570K +$108K +263,787 +21%
UOC
18
UBS O'Connor
Illinois
$470K – – –
GF
19
Gabelli Funds
New York
$266K – – –
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
$233K – – –
TL
21
TowerView LLC
New York
$228K – – –
Millennium Management
22
Millennium Management
New York
$190K – – –
BMO
23
Beck Mack & Oliver
New York
$177K – – –
Goldman Sachs
24
Goldman Sachs
New York
$172K +$8.41K +20,608 +5%
SAM
25
Silverback Asset Management
North Carolina
$171K +$184K +450,000 New
1
2 3 4

GCVRZ Hedge Fund Activity: Q2 2017 in Review

115 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q2 2017, worth a combined $57M — down 15% from $67.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new GCVRZ positions and 7 closed out — a net gain of 4 holders — while 20 added to existing stakes and 12 trimmed.

The largest buyer was Stonehill Capital Management, adding an estimated $2.55M. The largest seller was PointState Capital, exiting entirely with an estimated $3.29M sold.

  • 115 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q2 2017, up from 111 in Q1 2017.
  • Funds reported $57M of Sanofi Contingent Value Rights stock for Q2 2017, down 15% quarter-over-quarter.
  • 11 funds opened new Sanofi Contingent Value Rights positions in Q2 2017 and 7 closed out, a net change of +4 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q2 2017 was Stonehill Capital Management, an estimated $2.55M added.
  • The largest Sanofi Contingent Value Rights seller in Q2 2017 was PointState Capital, an estimated $3.29M sold.

Based on aggregated 13F filings for Q2 2017.